[18 F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: A prospective study of 210 patients

BJU International

Volumn 110, Issue 11, 2012, Pages 1666-1671

  Poulsen, Mads H ^a   Bouchelouche, Kirsten ^a   Høilund Carlsen, Poul F ^a   Petersen, Henrik ^a   Gerke, Oke ^a   Steffansen, Signe Inglev ^a   Marcussen, Niels ^a,b   Svolgaard, Niels ^a   Vach, Werner ^c   Geertsen, Ulla ^a   Walter, Steen ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

choline; FCH; lymph node staging; PET; PET CT; prostate cancer

Indexed keywords

FLUOROMETHYLCHOLINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUOROMETHYLCHOLINE;

ADULT; AGED; BONE METASTASIS; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; ARTICLE; BONE TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; LYMPH NODE; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SCINTISCANNING;

AGED; BONE NEOPLASMS; CHOLINE; FLUORINE RADIOISOTOPES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84870875566     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11150.x     Document Type: Review

References (31)

1. Heidenreich A, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
2. Abdollah F, Sun M, Briganti A, et al,. Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. BJU Int 2011; 108: 1769-75
3. Briganti A, Blute ML, Eastham JH, et al,. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 55: 1251-65
4. Weckermann D, Dorn R, Holl G, Wagner T, Harzmann R,. Limitations of radioguided surgery in high-risk prostate cancer. Eur Urol 2007; 51: 1549-56
5. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR,. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008; 112: 307-14
6. Kuban DA, Thames HD, Levy LB, et al,. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57: 915-28
7. Van PH, Joniau S,. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008; 53: 253-9
8. Bott SR,. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004; 7: 211-6
9. Giovacchini G, Picchio M, Coradeschi E, et al,. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010; 37: 301-9
10. Bouchelouche K, Turkbey B, Choyke P, Capala J,. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep 2010; 11: 180-90
11. DeGrado TR, Baldwin SW, Wang S, et al,. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42: 1805-14
12. DeGrado TR, Coleman RE, Wang S, et al,. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61: 110-7
13. Kryza D, Tadino V, Filannino MA, Villeret G, Lemoucheux L,. Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer. Nucl Med Biol 2008; 35: 255-60
14. Teras M, Tolvanen T, Johansson JJ, Williams JJ, Knuuti J,. Performance of the new generation of whole-body PET/CT scanners: discovery STE and Discovery VCT. Eur J Nucl Med Mol Imaging 2007; 34: 1683-92
15. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE,. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002; 43: 92-6
16. Altman DG, Machin D, Bryant TN, Gardner MJ,. Statistics with Confidence, 2nd edn. London: BMJ Books, 2000
17. Beheshti M, Imamovic L, Broinger G, et al,. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254: 925-33
18. Schiavina R, Scattoni V, Castellucci P, et al,. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54: 392-401
19. De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ,. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003; 44: 331-5
20. Bansal A, Shuyan W, Hara T, Harris RA, DeGrado TR,. Biodisposition and metabolism of [(18)F]fluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats. Eur J Nucl Med Mol Imaging 2008; 35: 1192-203
21. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G,. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009; 70: 382-92
22. Mavi A, Basu S, Cermik TF, et al,. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol 2009; 11: 369-78
23. Mavi A, Urhan M, Yu JQ, et al,. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006; 47: 1440-6
24. Wyss MT, Weber B, Honer M, et al,. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004; 31: 312-6
25. Bouchelouche K, Capala J, Oehr P,. Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol 2009; 21: 469-74
26. 18F-Fluoride PET/CT compared with MRI. Available at: http://www.aua2011.org/abstracts/printpdf.cfm?ID=302. Accessed February 2012
27. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I,. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47: 287-97
28. Schirrmeister H, Guhlmann A, Elsner K, et al,. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999; 40: 1623-9
29. Langsteger W, Balogova S, Huchet V, et al,. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011; 55: 448-57
30. Hovels AM, Heesakkers RA, Adang EM, et al,. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63: 387-95
31. Rosenthal SA, Haseman MK, Polascik TJ,. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 2001; 7: 27-37